US EditionPositive Results from Phase 3 OptiTROP-Lung04 Trial of Sacituzumab Tirumotecan Presented at ESMO Presidential Symposium and Simultaneously Published in NEJM
- The Phase 3 OptiTROP-Lung04 trial presented results of sacituzumab tirumotecan for EGFR-mutated non-small cell lung cancer, reported by Professor Li Zhang from Sun Yat-sen University Cancer Center.
- Sacituzumab tirumotecan improved progression-free survival by 51% compared to chemotherapy, with a hazard ratio of 0.49 and P<0.0001.
- The trial also showed sacituzumab tirumotecan reduced the risk of death by 40%, with a hazard ratio of 0.6 and P=0.001.
- Overall response rate for sacituzumab tirumotecan was 60.6%, significantly higher than 43.1% for chemotherapy.
77 Articles
77 Articles
The Manila Times
Laotian TimesThe New England Journal of Medicine Publishes Results of Phase III OptiTROP-Lung04 Study of Sacituzumab Tirumotecan in Advanced EGFR-TKI-Resistant NSCLC
**media[789736]**After a median follow-up of 18.9 months, the median PFS was 8.3 months in the sac-TMT group and 4.3 months in the chemotherapy group (hazard ratio (HR), 0.49; 95% confidence interval (CI), 0.39 to 0.62; two-sided P OS was significantly longer with sac-TMT than with chemotherapy (HR, 0.60; 95% CI, 0.44 to 0.82; two-sided P=0.001); 18-month OS rate was 65.8% and 48.0%, respectively. In the supplementary analysis, in which data wer…
LoudounTimes.com
Positive Results from Phase 3 OptiTROP-Lung04 Trial of Sacituzumab Tirumotecan Presented at ESMO Presidential Symposium and Simultaneously Published in NEJM
CHENGDU, China , Oct. 19, 2025 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (the "Company") announced that at the 2025 European Society for Medical Oncology (ESMO) Congress held in Berlin, Germany, results from a Phase 3 OptiTROP-Lung04 trial of the…
Coverage Details
Bias Distribution
- 63% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
